The Clinical Translation Programme, led by Dr Jonathan Krell, is a crucial delivery component of the OCARC. It is integrated with all the respective research themes within OCARC, and the multi-agency clinical trials infrastructure across Imperial, that enables clinical trials and translational studies to be conducted with a high level of innovation and quality, as well as appropriate governance.
As such, we work closely with:
- Cancer Research UK Imperial Centre: Cancer Clinical Trials Section (CCTS)
- Imperial Experimental Cancer Medicine Centre (ECMC) / Imperial Cancer Biomarker Resource Centre (ICBRC)
- Imperial Tissue Bank
- Imperial Biomedical Research Centre (BRC)
- Imperial College Academic Health Science Centre (AHSC)
The overall aims of this programme are:
- To translate research into patient evaluation through translational studies using clinical material
- To move studies and ideas into the clinic for evaluation and possible patient benefit through OCARC developed clinical trials
Clinical Trials and Translational Studies
Clinical translation, where we identify and fast-track new treatments from 'bench to bedside' is central to OCARC's aims. Find out about the wide range of clinical trials and translational studies in which the Research Centre is involved.